Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Operating Expenses: 2018-2024

Historic Operating Expenses for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Dec 2024 value amounting to $248.0 million.

  • Arcturus Therapeutics Holdings' Operating Expenses fell 35.77% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $175.9 million, marking a year-over-year decrease of 26.98%. This contributed to the annual value of $248.0 million for FY2024, which is 1.21% up from last year.
  • Arcturus Therapeutics Holdings' Operating Expenses amounted to $248.0 million in FY2024, which was up 1.21% from $245.0 million recorded in FY2023.
  • Arcturus Therapeutics Holdings' 5-year Operating Expenses high stood at $248.0 million for FY2024, and its period low was $81.1 million during FY2020.
  • Its 3-year average for Operating Expenses is $228.9 million, with a median of $245.0 million in 2023.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Operating Expenses soared by 165.49% in 2021, and later decreased by 9.94% in 2022.
  • Yearly analysis of 5 years shows Arcturus Therapeutics Holdings' Operating Expenses stood at $81.1 million in 2020, then spiked by 165.49% to $215.2 million in 2021, then fell by 9.94% to $193.8 million in 2022, then grew by 26.41% to $245.0 million in 2023, then rose by 1.21% to $248.0 million in 2024.